Anbio Biotechnology Class A Ordinary Shares (NNNN) vs Entrada Therapeutics, Inc. (TRDA)

A side-by-side comparison of Anbio Biotechnology Class A Ordinary Shares and Entrada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Anbio Biotechnology Class A Ordinary Shares logo
NNNN
Anbio Biotechnology Class A Ordinary Shares
$215M
$4.90HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Entrada Therapeutics, Inc. logo
TRDA
Entrada Therapeutics, Inc.
$210M
$5.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — NNNN vs TRDA

growth of $100 · dividends reinvested · last 2y
NNNN -16.3% (-8.5%/yr)TRDA -57.8% (-35.1%/yr)NNNN compounded faster over this window
0200400600800Start $1002026$84$42
NNNN TRDA

NNNN vs TRDA: by the numbers

  • •NNNN is the larger company ($215M vs $210M market cap).
  • •NNNN is profitable (74.06% net margin) while TRDA runs a net loss (-3537.73%).

Metrics side by side

Valuation

MetricNNNNTRDA
P/S ratioN/A44.90
P/B ratio7.130.90

Profitability

MetricNNNNTRDA
Gross margin87.24%83.89%
Operating margin66.70%-613.66%
Net margin74.06%-3537.73%
ROE21.24%-71.02%
ROIC19.13%-63.61%

Frequently asked

Is NNNN or TRDA more profitable?
NNNN runs the higher net margin — NNNN at 74.06% versus TRDA at -3537.73%.

Go deeper

Full NNNN analysisFull TRDA analysisInteractive comparison tool

Dig into the metrics

Anbio Biotechnology Class A Ordinary Shares ROEEntrada Therapeutics ROEAnbio Biotechnology Class A Ordinary Shares operating marginEntrada Therapeutics operating marginAnbio Biotechnology Class A Ordinary Shares revenue growthEntrada Therapeutics revenue growthAnbio Biotechnology Class A Ordinary Shares free cash flowEntrada Therapeutics free cash flow

Anbio Biotechnology Class A Ordinary Shares & Entrada Therapeutics appear in these rankings

Highest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.